Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
Authors Hwang YH
Received 5 November 2013
Accepted for publication 8 November 2013
Published 18 December 2013 Volume 2014:8 Pages 71—72
Checked for plagiarism Yes
Young Hoon Hwang
Department of Ophthalmology, Konyang University, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Seoul, Korea
I read with interest the article entitled "Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension" by Lanzl et al.1 I have also experienced similar treatment outcomes in Korean patients. In Korea, preservative-free tafluprost (Taflotan-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) was introduced to the ophthalmic market in October 2012. Thus far, no data have been published on the efficacy and tolerability of preservative-free tafluprost in Korean patients. Thus, I investigated the intraocular pressure (IOP)-lowering efficacy and safety of preservative-free tafluprost in treatment-naïve Korean patients with glaucoma.
View original paper by Lanzl and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]